Steadtrust LLC Makes New $633,000 Investment in Bristol Myers Squibb Company $BMY

Steadtrust LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,732 shares of the biopharmaceutical company’s stock, valued at approximately $633,000.

Several other hedge funds also recently bought and sold shares of BMY. Vanguard Group Inc. boosted its holdings in shares of Bristol Myers Squibb by 0.5% during the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after purchasing an additional 1,058,803 shares during the last quarter. State Street Corp boosted its holdings in shares of Bristol Myers Squibb by 2.0% during the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock worth $4,356,445,000 after purchasing an additional 1,855,238 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Bristol Myers Squibb by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after purchasing an additional 432,158 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Bristol Myers Squibb by 11.5% during the third quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company’s stock worth $818,105,000 after purchasing an additional 1,873,618 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Bristol Myers Squibb by 8.4% during the third quarter. Legal & General Group Plc now owns 17,075,743 shares of the biopharmaceutical company’s stock worth $770,116,000 after purchasing an additional 1,317,199 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.09% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Wells Fargo & Company restated an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. UBS Group restated a “buy” rating and set a $70.00 price objective on shares of Bristol Myers Squibb in a report on Friday, March 6th. Scotiabank reiterated a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Trading Down 2.8%

NYSE:BMY opened at $57.68 on Wednesday. The business’s 50-day moving average is $59.51 and its two-hundred day moving average is $52.94. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The firm has a market capitalization of $117.77 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same period last year, the business earned $1.67 earnings per share. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.4%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.